<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47610">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486406</url>
  </required_header>
  <id_info>
    <org_study_id>M14-748</org_study_id>
    <secondary_id>2015-000111-41</secondary_id>
    <nct_id>NCT02486406</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects</brief_title>
  <acronym>ZIRCON</acronym>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this three part study is to evaluate the pharmacokinetics (Part 1),
      safety/efficacy (Part 2), and long-term follow-up (Part 3) of ombitasvir (OBV), paritaprevir
      (PTV), ritonavir (RTV) with or without dasabuvir (DSV) and with or without ribavirin (RBV)
      in pediatric subjects with genotype 1 or 4 chronic hepatitis C virus (HCV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part1: Maximum plasma concentration (Cmax) of OBV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum plasma concentration (Cmax) of PTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum plasma concentration (Cmax) of DSV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum plasma concentration (Cmax) of RTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of OBV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of PTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of DSV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of RTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Lowest plasma concentration (Ctrough) of OBV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Lowest plasma concentration (Ctrough) of PTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Lowest plasma concentration (Ctrough) of DSV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Lowest plasma concentration (Ctrough) of RTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Percentage of participants with sustained virologic response 12 weeks after the last actual dose of study drug (SVR12).</measure>
    <time_frame>Either 24 weeks or 36 weeks after starting study drug depending on treatment duration (12 or 24 weeks of treatment respectively).</time_frame>
    <description>HCV RNA &lt; Lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Percentage of participants who relapse out of participants who achieved sustained virologic response (SVR) in Part 1 or Part 2 of the study.</measure>
    <time_frame>Any time up to the last follow-up in this study, approximately 4 years.</time_frame>
    <description>Relapse is defined as confirmed HCV RNA ≥ LLOQ for a subject with HCV RNA &lt; LLOQ at Final Treatment Visit who completes treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Percentage of participants who have new HCV infection</measure>
    <time_frame>Any time up to the last follow-up in this study, approximately 4 years.</time_frame>
    <description>The percentage of participants who have new HCV infection at any time up to the last follow-up in this study out of participants who achieved SVR in Part 1 or Part 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Percentage of subjects who achieve SVR12 summarized by formulation and age group and across all subjects on the adult formulations.</measure>
    <time_frame>24 weeks after starting study drug depending on treatment duration.</time_frame>
    <description>HCV RNA &lt; LLOQ 12 weeks after the last actual dose of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Percentage of participants who achieve SVR24 by formulation and age group, across all the subjects on the final dose formulations, and across all subjects on the adult formulations.</measure>
    <time_frame>36 weeks after starting study drug depending on treatment duration.</time_frame>
    <description>HCV RNA &lt; LLOQ 24 weeks after the last actual dose of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Percentage of participants with Alanine aminotransferase (ALT) normalization during treatment</measure>
    <time_frame>During the treatment period (either 12 or 24 weeks)</time_frame>
    <description>ALT less than or equal to upper limit of normal (ULN) at the final treatment visit for participants with ALT greater than ULN at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on height</measure>
    <time_frame>Any time up to the last follow-up in this study, approximately 4 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on waist circumference</measure>
    <time_frame>Any time up to the last follow-up in this study, approximately 4 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on tanner staging</measure>
    <time_frame>Any time up to the last follow-up in this study, approximately 4 years.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Genotype 1b, with or without compensated cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 4, with or without compensated cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ombitasvir</intervention_name>
    <arm_group_label>Genotype 1b, with or without compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 4, with or without compensated cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paritaprevir</intervention_name>
    <arm_group_label>Genotype 1b, with or without compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 4, with or without compensated cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <arm_group_label>Genotype 1b, with or without compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 4, with or without compensated cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasabuvir</intervention_name>
    <arm_group_label>Genotype 1b, with or without compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 4, with or without compensated cirrhosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Positive anti-HCV Ab and HCV RNA greater than or equal to 1000 IU/mL at the time of
             screening.

          2. HCV genotype 1 for enrollment into Part 1 and genotype 1 or 4 for enrollment into
             Part 2.

          3. Parent or legal guardian with the willingness and ability to provide written informed
             consent and participant willing and able to give assent, as appropriate for age and
             country.

        Exclusion Criteria:

          1. Women who are pregnant, breastfeeding or are considering becoming pregnant

          2. Use of known strong inducers and inhibitors (e.g., gemfibrozil) of cytochrome P450
             2C8 (CYP2C8) in participants receiving dasabuvir, or strong or moderate inducers of
             CYP3A, within 2 weeks or 10 half lives, whichever is longer, of the respective
             medication/supplement prior to study drug administration.

          3. Positive test result for Hepatitis B surface antigen (HbsAg) or anti-HIV antibody
             (HIV Ab) test.

          4. Current enrollment in another interventional clinical study, previous enrollment in
             this study, prior or current use of any investigational or commercially available
             anti-HCV agents other than IFNs or RBV or receipt of any investigational product
             within 6 weeks prior to study drug administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Betty Yao, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie_Call Center</last_name>
    <phone>847-283-8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136774</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136774, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137017</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-7106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 137017, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136830</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136830, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137015</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 137015, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136775</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137174</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 137174, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136831</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136831, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136431</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136431, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136589</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7596</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136589, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136408</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137018</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 137018</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136590</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136590, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137019</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136910</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136911</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141206</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 1C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141620</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141618</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 142883</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136832</name>
      <address>
        <city>San Juan</city>
        <zip>00912</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137096</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137098</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137094</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137097</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141825</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139405</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 13, 2017</lastchanged_date>
  <firstreceived_date>June 17, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Genotype 4</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Hepatitis C Genotype 1</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
